Generic Name and Formulations:
Beclomethasone dipropionate 40mcg/inh, 80mcg/inh; metered-dose aerosol with a dose counter; CFC-free.
Indications for QVAR:
Maintenance treatment of asthma as prophylactic therapy. Asthma requiring systemic corticosteroid therapy, to reduce need for systemic corticosteroids.
Previously on bronchodilators alone: initially 40–80mcg twice daily; max 320mcg twice daily. Previously on inhaled corticosteroids: initially 40–160mcg twice daily; max 320mcg twice daily. Rinse mouth after use.
<5yrs: not recommended. 5–11yrs: initially 40mcg twice daily; max 80mcg twice daily. Rinse mouth after use.
Not for treatment of acute attacks.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually). Transferring from systemic corticosteroids: see literature. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Headache, pharyngitis, rhinitis, pain; rare: hypersensitivity reactions, psychiatric events and behavioral changes (esp in children).
Inhalation aerosol (w. dose counter)—8.7g (120 inh)
- 8.7g of 80mcg inhalers (Qty:1)
- appx. price $207.00
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- Spiriva Respimat Gains Indication and New Dosage Strength
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC: Novel Lyme Disease Pathogen Discovered
- FDA to Review Rexulti as Maintenance Therapy for Schizophrenia
- Case Illustrates Impact of Dabigatran-Phenytoin Interaction
- Real-World Data on Retreating HCV Patients With NS5A Inhibitor Failure
- Tazemetostat Granted Orphan Drug Status for Rare, Aggressive Cancers